Samarth Kulkarni Sells 30,000 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total value of $1,668,600.00. Following the transaction, the chief executive officer now directly owns 196,540 shares in the company, valued at $10,931,554.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Monday, October 14th, Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $49.79 on Thursday. CRISPR Therapeutics AG has a 52-week low of $43.42 and a 52-week high of $91.10. The stock has a market capitalization of $4.25 billion, a PE ratio of -17.59 and a beta of 1.67. The company has a 50-day simple moving average of $47.80 and a two-hundred day simple moving average of $52.12.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period last year, the business posted ($1.41) EPS. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CRSP has been the subject of several research analyst reports. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. Finally, Chardan Capital reduced their price objective on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $74.94.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC lifted its stake in shares of CRISPR Therapeutics by 10.1% in the 1st quarter. ProShare Advisors LLC now owns 5,791 shares of the company’s stock valued at $395,000 after purchasing an additional 530 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at $1,723,000. Blair William & Co. IL lifted its holdings in shares of CRISPR Therapeutics by 8.2% in the 1st quarter. Blair William & Co. IL now owns 147,890 shares of the company’s stock worth $10,080,000 after acquiring an additional 11,190 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of CRISPR Therapeutics by 2.9% during the 1st quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock worth $111,564,000 after purchasing an additional 46,148 shares during the period. Finally, Orion Capital Management LLC boosted its position in shares of CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.